Study Shows Nasal Spray Protects Against Any Flu Strain
The antibody CR9114 shows promise in combating future flu pandemics as it appears to neutralize any influenza virus.
FDA Approves Merck’s KEYTRUDA QLEX for Solid Tumor Indications
The U.S. Food and Drug Administration has approved KEYTRUDA QLEX (pembrolizumab and berahyaluronidase alfa-pmph) injection for subcutaneous administration in adults across most solid tumor indications for KEYTRUDA (pembrolizumab).
New Assay to Accurately Measure FXI Levels During IVIG Therapy
GC Biopharma has developed a proprietary enzyme-linked immunoassay (ELISA) that effectively mitigates heterophilic antibody interference to precisely measure factor XI (FXI) levels.
Novel Flu Vaccine Offers Broad Protection Against Multiple Flu Viruses
A potentially effective mucosal vaccine platform has been developed to encourage broad, protective immunity against multiple influenza virus infections.
Flu Vaccine Even with Infection Reduces Risk of Heart and Stroke
A new study shows that influenza vaccination may help protect against heart attack and stroke even when it does not prevent people from getting the flu.
High-Dose Flu Vaccine Significantly Lowers Risk of Developing Alzheimer’s
Researchers have found that adults 65 and older who received a high-dose influenza vaccine had a significantly lower risk of developing Alzheimer’s disease compared to those who received the standard dose.
FDA Approves Gene Therapy for Rare Immune Disorder
FDA has approved Kresladi (marnetegragene autotemcel), the first gene therapy for the treatment of severe leukocyte adhesion deficiency type I.
IVIG Effective in Treating Infants with HDFN
A recent study has found intravenous immune globulin (IVIG) therapy in infants with hemolytic disease of the fetus and newborn (HDFN) found that it could be beneficial.
Airborne Spread of Flu Is Reduced by Targeting Two Flu Proteins
A new study demonstrates a way to stop the influenza virus from leaping from one host to the next while continuing to keep the virus from replicating inside the host.
AREXVY RSV Vaccine Approved for Expanded Age Indication
The U.S. Food and Drug Administration has expanded the approved age indication of AREXVY to adults aged 18 to 49 years at increased risk for lower respiratory tract disease caused by RSV.